Status:
COMPLETED
Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.
Lead Sponsor:
Ullevaal University Hospital
Collaborating Sponsors:
The Norwegian Council for Cardiovascular Diseases.
Ada and Hagbart Waages Humanitarian and Charity Foundation
Conditions:
Coronary Heart Disease
Angina Pectoris
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
In the ASCET study, 1000 patients with documented coronary heart disease will be randomized to either continued treatment with aspirin 160 mg/d or change to clopidogrel 75mg/d. Clinical endpoints will...
Detailed Description
Background: Aspirin is widely used as an antiplatelet drug in patients with coronary heart disease. Despite documented clinical benefit, many patients on aspirin still experience severe cardiovascular...
Eligibility Criteria
Inclusion
- Stable, symptomatic coronary heart disease, verified by coronary angiography, being treated with angioplasty/stent implantation (PCI) or not.
Exclusion
- Indication for warfarin treatment.
- Indication for or contraindication to the study drugs.
- Pregnancy or breast-feeding.
- Malignancy that may interfere with life expectancy.
- Psychiatric disease, mental retardation, dementia, drug abuse, alcoholism or conditions that can severely reduce compliance.
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1001 Patients enrolled
Trial Details
Trial ID
NCT00222261
Start Date
April 1 2003
End Date
July 1 2010
Last Update
March 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ullevaal University Hospital
Oslo, Norway, 0407